Sign In
Buy BIO
$304.83
-1.30 (-0.425%)
At Close: Jun 03, 2026
Tonix Pharmaceuticals to Participate in the 2025 BIO CEO & Investor Conference
07:00am, Wednesday, 05'th Feb 2025
CHATHAM, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of develop
Has BioRad Laboratories (BIO) Outpaced Other Medical Stocks This Year?
10:45am, Tuesday, 04'th Feb 2025
Here is how Bio-Rad Laboratories (BIO) and Certara, Inc. (CERT) have performed compared to their sector so far this year.
Protalix BioTherapeutics to Participate in the 2025 BIO CEO & Investor Conference
06:50am, Tuesday, 04'th Feb 2025
Corporate presentation scheduled for Tuesday, February 11, 2025 at 10:15 AM EST CARMIEL, Israel , Feb. 4, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical
Lifecore Biomedical to Participate in 2025 BIO CEO & Investor Conference
07:00am, Monday, 03'rd Feb 2025
CHASKA, Minn., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Lifecore Biomedical, Inc. (NASDAQ: LFCR) (“Lifecore”), a fully integrated contract development and manufacturing organization (“CDMO”), today a
Reviva to Participate in the 2025 BIO CEO & Investor Conference
08:00am, Thursday, 30'th Jan 2025
CUPERTINO, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a late-stage pharmaceutical company developing therapies
Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025
05:00pm, Monday, 27'th Jan 2025
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, will report its financial results for t
BKYI: Wyoming Department of Education Chooses BIO-key PortalGuard IDaaS Platform to Secure Identity and Access Management for Critical Systems and Data.
BKYI: 3 Higher-Ed Customers with 30,000+ Users Migrate to BIO-key's PortalGuard IDaaS Cloud Platform for Streamlined Operations & Enhanced Access Mgt.
Why Bio-Rad Stock is an Apt Pick for Your Portfolio Right Now
07:16am, Friday, 17'th Jan 2025
BIO's robust performance of the ddPCR platform and clinical diagnostics momentum bodes well for investors.
ATLANTIC CITY, NJ and HOLMDEL, NJ / ACCESSWIRE / January 10, 2025 / BIO-key® International, Inc. (NASDAQ:BKYI), an innovative provider of identity and access management (IAM) solutions featuring Iden
BIO-TECHNE TO PRESENT AT PHACILITATE ADVANCED THERAPIES WEEK 2025
07:00am, Wednesday, 08'th Jan 2025
MINNEAPOLIS , Jan. 8, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced it will showcase its new ProPak™ GMP cytokines, alongside its portfolio of innovative products and so
BIO-TECHNE SUCCESSFUL ON SECOND CLAIM OF REVERSE ENGINEERING BY MILTENYI BIOTEC
07:00am, Tuesday, 07'th Jan 2025
MINNEAPOLIS , Jan. 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it prevailed on another claim that Miltenyi Biotec B.V. & Co. KG commercialized antibodies develo
Bio-Rad's Management to Host Investor Meetings at J.P. Morgan's 43rd Annual Healthcare Conference
04:30pm, Thursday, 02'nd Jan 2025
HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced that the company's Chie
New Jersey Based Biometric & Cyber Security Solutions Provider BIO-key (BKYI) to Present/Participate at DealFlow's Atlantic City Microcap Conf. 1/29 & 1/30
BIO-TECHNE TO PRESENT AT THE 43rd ANNUAL J.P. MORGAN HEALTHCARE CONFERENCE
07:00am, Friday, 20'th Dec 2024
MINNEAPOLIS , Dec. 20, 2024 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Kim Kelderman, President and Chief Executive Officer, will present at the 43rd Annual J.P. Morga
